NIH Highlighted Topic: Accelerating Disease Prevention Research by New Approach Methodologies
Executive Summary
The National Institutes of Health has published a Highlighted Topic titled "Accelerating Disease Prevention Research by New Approach Methodologies." It signals that four NIH awarding components, the National Cancer Institute (NCI), the National Center for Advancing Translational Sciences (NCATS), the National Institute on Aging (NIA), and the National Institute on Drug Abuse (NIDA), want to fund the development, validation, and use of human-relevant New Approach Methodologies that model precursor conditions and the process by which those conditions progress into overt disease.
The gap NIH names is specific and narrow. NAMs exist. NAMs that model precursor states, things like precancer, prediabetes, and preclinical Alzheimer's disease, and that capture the dynamics of progression rather than a static snapshot, do not exist in sufficient number. NIH calls this a high-priority unmet need. If your platform can model a disease before it becomes a disease, you are inside the target.
For a small business, the practical translation is this: there is no new application portal and no new deadline attached to this topic. A Highlighted Topic is a demand signal, not a Notice of Funding Opportunity. You capture the funding by submitting to the NIH SBIR or STTR parent announcement, requesting assignment to whichever of the four Institutes best fits your science, and aligning your Specific Aims to that Institute's stated areas of interest.
The topic was posted on September 3, 2026 and expires on September 3, 2028. Budget guidance varies substantially by Institute, which is the single most consequential planning fact on this page. The SBA statutory guidelines for the current cycle are $323,090 for Phase I and $2,153,927 for Phase II, but the participating component table in the parent SBIR announcement lists Phase I limits as high as $700,000 for NCI and NIA, while NCATS operates at the statutory guideline.
If you build organoids, microphysiological systems and organ-on-a-chip platforms, iPSC-derived tissue or immune models, bioengineered human tissues, advanced biomaterials for human-derived models, in silico or AI-based predictive models, or combinatorial NAMs, this is one of the broadest and best-signposted funding openings NIH has published for the tools and platforms community.
At a Glance
Topic title: Accelerating Disease Prevention Research by New Approach Methodologies
Issuing agency: National Institutes of Health, U.S. Department of Health and Human Services
Awarding components: NCI, NCATS, NIA, and NIDA
Non-awarding participating offices: ORWH, the Office of Autoimmune Disease Research in ORWH (OADR-ORWH), and the Tribal Health Research Office (THRO)
Type: NIH Highlighted Topic. This is not a Notice of Funding Opportunity.
Post date: September 3, 2026
Expiration date: September 3, 2028
Recommended small business mechanism: NIH SBIR (R43 and R44) or NIH STTR (R41 and R42) parent announcement
Current parent announcements: PA-27-100 for SBIR, PA-27-102 for STTR, PA-27-101 for the Phase IIB Strategic Breakthrough Award, and PAR-27-098 for the Commercialization Readiness Pilot
Standard annual due dates: January 5, April 5, and September 5
SBA statutory guidelines this cycle: $323,090 Phase I, $2,153,927 Phase II, $4,191,495 CRP
Component Phase I limits in the parent SBIR table: up to $700,000 for NCI and NIA, with NCATS at the statutory guideline. Confirm with the Institute before budgeting above the guideline.
Cost share: none for Phase I or Phase II. Phase IIB requires 100 percent third-party matching funds.
Equity dilution: none. This is non-dilutive federal funding.
Profit or fee: allowable, must be in the budget at submission, and normally will not exceed 7 percent of total costs
Funding signals: NCATS states it may dedicate available funds to this topic area. NIDA states it may give special consideration to meritorious applications in this topic area.
Small business specific contact: NCI has designated Linda Zane, Ph.D. for small business product development and commercialization of NAMs, reachable at NCI-HT-NAM@nih.gov
Broader initiative alignment: Make America Healthy Again initiative, New Approach Methodologies effort
What This Opportunity Actually Is
An NIH Highlighted Topic is a published statement of scientific interest from one or more NIH Institutes, Centers, and Offices. It tells the research community that an area of science is a priority without creating a separate funding announcement, a separate deadline, or a separate review process. There is no topic-specific number to search for on Grants.gov, and applications are not reviewed against other applications to the topic.
What it does do for a small business is threefold. It identifies which Institutes are receptive, which determines your assignment request and which program officer you call. It supplies the vocabulary that program staff and reviewers are already using internally, which is what your Specific Aims should mirror. And in two cases here it creates an explicit funding advantage: NCATS states it may dedicate available funds to applications in this topic area depending on the availability of funds, the number of meritorious applications, and competing priorities, and NIDA states it may give special consideration to meritorious applications in the topic area.
What it does not do is guarantee a set-aside or bypass peer review. Your application competes on scientific merit through the standard NIH study section route, and the topic language is a positioning advantage rather than a shortcut.
Which Institute Should You Target?
This is the decision that matters most on this topic, because four awarding components with materially different missions and budget ceilings are participating, and your assignment request determines which one reads your application.
NCI, if your work touches precancer or cancer prevention. NCI published the most detailed and most product-oriented set of interests here, covering human-derived precancerous organoids, iPSC-derived and bioengineered human tissue and immune system models of tumorigenesis, advanced biomaterials enabling human-derived NAMs, NAMs for discovery of preventive, interceptive, or reversive agents, NAMs for biomarker discovery supporting early detection and risk stratification, and microphysiological and combinatorial NAMs for predicting human safety and toxicity of candidate prevention agents. NCI also listed eight named scientific contacts for this topic, including one specifically for small business product development and commercialization of NAMs. That is an unusually strong signal that NCI expects and wants small business applications here.
NCATS, if your platform is disease-agnostic. NCATS is interested in NAMs that reveal the mechanisms of drug-induced organ injury so those reactions can be prevented before clinical symptoms emerge. The framing is deliberately not tied to one disease, which makes this the right door for a platform company whose technology is a tool rather than a disease model. NCATS asks for innovative, scalable, and reproducible platforms that enable earlier intervention, reduce reliance on traditional animal models, and generate broadly applicable knowledge. Note that scalability and reproducibility are named explicitly, which for a small business means manufacturing consistency and assay robustness are scientific aims, not afterthoughts.
NIA, if your work concerns aging, resilience, or dementia. NIA wants NAMs that identify biomarkers, protective pathways, and preventive therapeutics for age-related conditions including Alzheimer's disease and related dementias. Its interests include person-specific, cross-species, and combinatorial NAMs; neuronal and peripheral tissue NAMs derived from individuals with exceptional longevity, cognitive superagers, or people showing resistance or resilience to AD and ADRD, used to identify protective pathways and test whether those pathways can reduce or reverse disease phenotypes in patient-derived iPSCs; and in silico NAMs that model behavioral, cognitive, and functional phenotypes alongside extrinsic risk factors. The resilience donor angle is distinctive and worth noting: NIA is asking for models built from people who did not get sick.
NIDA, if your work concerns addiction biology or substance use. NIDA seeks human-relevant NAMs that accelerate addiction research and intervention discovery, including iPSCs, organoids, and bioengineered tissues that identify molecular changes induced by addictive drugs and mechanisms of vulnerability; tools and methods including in silico models that integrate and analyze epidemiological and electronic health record data to surface mechanisms, biomarkers, and candidate drugs; and NAMs that decipher interactions between biological factors such as age and sex, behavioral factors such as exercise, and environmental factors such as nutrition and substance exposure. NIDA's inclusion of data integration work makes this the most software-friendly of the four.
If your technology plausibly fits more than one, contact more than one program officer before choosing. Assignment requests are not binding on NIH, but an application written to a specific Institute's language and referred elsewhere reads as a poor fit to whoever receives it.
Which NIH Mechanism Should a Small Business Use?
Small businesses should apply through the NIH SBIR or STTR parent announcement and request assignment to the Institute whose interests match.
NIH Parent SBIR, currently PA-27-100 (R43 and R44). The default route for most companies. It accepts Phase I, Phase II, Direct to Phase II, and Fast-Track applications. Use it when your company performs the majority of the research and your Principal Investigator is primarily employed by the company.
NIH Parent STTR, currently PA-27-102 (R41 and R42). Use this when the project depends on a formal partnership with a U.S. nonprofit research institution. STTR requires at least 40 percent of the research at the small business and at least 30 percent at a single partner institution. This is the natural route for a company commercializing licensed organoid, iPSC, or microphysiological system technology where the originating academic lab retains essential capability, and for projects needing access to donor cohorts such as NIA's exceptional longevity and resilience populations.
Direct to Phase II. If you already have the feasibility data a Phase I would generate, and you never received a Phase I award for that project, you can apply straight to Phase II. This authority is SBIR only and is not available under STTR. Many NAMs companies with a validated platform in one disease context and new data in a precursor context are strong candidates here.
Fast-Track. Phase I and Phase II submitted together and reviewed once. It compresses the funding gap but requires a fully developed Phase II plan at first submission. Poor fit when Phase I results would change the Phase II design, which is common in early model development where the qualification strategy depends on what the first characterization shows.
Phase IIB Strategic Breakthrough Award, currently PA-27-101 (R44). For companies that have completed an NIH SBIR or STTR Phase II and need to bridge to commercialization. Requires documentation of not less than 100 percent matching funds from new private capital or from a government source other than a Phase I or Phase II SBIR or STTR award. Budget guidance varies by participating Institute.
Commercialization Readiness Pilot, currently PAR-27-098 (SB1). Funds late-stage technical assistance and product development that Phase II and Phase IIB cannot support, including specialized regulatory and qualification work. It permits more outsourcing than other mechanisms, though the small business must retain substantial project management and oversight. Note that NCI caps its CRP support well below the government-wide CRP figure, so contact NCI SBIR program staff before planning a CRP budget.
Funding Allowance
The ceiling on this topic depends on two layers, and on this particular topic the second layer varies more than usual because four Institutes are involved.
Layer one, the SBA statutory guidelines for the current cycle:
Phase I: up to $323,090 in total costs, for a project period of 6 months to 2 years
Phase II: up to $2,153,927 in total costs, for a project period of 1 to 3 years
Commercialization Readiness Pilot: up to $4,191,495 in total costs, for a project period of up to 3 years
Total funding support means direct costs, indirect costs, and fee combined. A reasonable profit or fee is allowable on SBIR and STTR awards, but it must be built into the budget at the time of application and normally will not exceed 7 percent of total costs. NIH does not adjust budgets after submission, so a budget requested at the wrong level cannot be corrected later.
Layer two, Institute-specific guidance. NIH holds SBA waivers permitting awards above the statutory guideline for specific approved topics, and each Institute publishes its own limits. For the four awarding components here:
NCI. The participating component table in the parent SBIR announcement lists a Phase I limit as high as $700,000. NCI's own program descriptions state that for waiver-eligible topics it generally funds Phase I applications up to $400,000 in total costs across up to 2 years, and will consider Phase II applications up to $2,250,000 across up to 3 years. NCI also runs a Phase IIB Bridge Award and caps its CRP support well below the government-wide figure.
NIA. Listed among the components with a Phase I limit as high as $700,000 in the parent announcement table.
NCATS. Operates at the stated statutory guideline rather than a waivered higher limit.
NIDA. Publishes waiver-topic guidance permitting Phase I requests above the standard guideline with a project period up to 1 year, and Phase II requests up to $2.5 million with a project period up to 3 years, where the research falls within NIDA's approved waiver topics and the justification is adequate.
Two cautions on the headroom. First, the ceiling in a component table is not the number that gets awarded. BW&CO's own analysis of a fiscal year 2026 NCI SBIR award slice found Phase I level awards ranging from roughly $305,000 to $404,000, with not one award in 44 records using the $700,000 headroom. The realistic planning number for an NCI SBIR Phase I is closer to $400,000. Building a program plan around a waivered Phase I budgets against an outcome that did not occur. Second, an Institute may reduce the recommended budget or shorten the award period for budgetary, administrative, or programmatic reasons even after a strong review score.
The practical instruction is the same across all four: identify your target Institute, then contact its program staff with a draft Specific Aims page before you set the budget. Institutes generally do not pre-approve budget waivers, but they will tell you whether your topic is waiver-eligible and whether the number you have in mind is realistic.
Timeline
The Highlighted Topic window runs from September 3, 2026 through September 3, 2028. Within that window you submit against the NIH standard small business receipt dates.
Standard annual due dates: January 5, April 5, and September 5. When a due date falls on a weekend or federal holiday, NIH moves it to the next business day. Applications are due by 5:00 p.m. local time of the applicant organization.
Cycles available under this topic:
September 2026 cycle: the September 5, 2026 date shifted to Tuesday, September 8, 2026 because of the weekend and the Labor Day holiday. Since the topic posted on September 3, this cycle is not realistically available.
January 5, 2027: the first realistic cycle for a company beginning preparation now.
April 5, 2027
September 5, 2027
January 5, 2028
April 5, 2028, the last full cycle before the topic expires in September 2028.
What the runway looks like: plan on roughly 9 months from submission to funds in the door. An application submitted in the January 2027 cycle typically reaches an earliest possible start date in the fall of 2027. Council decisions for the September and January cycles are often handled together, which is one reason experienced applicants do not treat deferring a cycle as costless.
Work backwards from your target date:
14 to 16 weeks out: identify your target Institute, contact its program officer, confirm responsiveness and waiver eligibility, and start or verify federal registrations
12 weeks out: lock the Specific Aims page and circulate it to program staff
8 weeks out: complete the research strategy, the commercialization plan, letters of support, and any donor cohort or tissue sourcing agreements
4 weeks out: full internal review, budget finalization, and subaward paperwork for any STTR or academic partner
1 week out: submit early to leave room for eRA Commons error correction
Registrations are the most common cause of a missed deadline. You need SAM.gov with a Unique Entity ID, the SBA Company Registry, eRA Commons, and Grants.gov. eRA Commons access depends on the SBA Company Registry being complete first. Allow six weeks or more and begin before you write anything.
Also note that parent announcements are reissued periodically. The current SBIR parent, PA-27-100, carries a closing date in early April 2027, well before this topic expires, so applicants targeting later cycles must confirm the active announcement number at the time of submission.
Detailed Overview of What NIH Is Looking For
The problem NIH is trying to solve
The topic's premise is that prevention research is bottlenecked by a missing class of research tools. Beyond established risk-reduction strategies such as lifestyle change and smoking cessation, NIH argues that studying the etiologic processes by which precursor conditions initiate and progress opens new prevention opportunities: actionable targets, biomarkers for early detection and risk stratification, and therapeutics designed to prevent or intercept precursors before they become manifest disease, or even to revert them to normal.
NIH is direct about why animal models alone will not get there. Animal models remain vital, and nearly every modern pharmaceutical agent reached human clinical data on the strength of animal data, but only about 10 percent of agents entering clinical trials obtain regulatory approval. NIH attributes this to inadequate drug target validation, absent human efficacy, and unmanageable toxicity, and argues that human-relevant research tools designed to bridge interspecies differences in pathophysiology, environmental exposure, and disease characteristics, combined with in silico and AI-based tools, can improve the predictability of human efficacy and safety.
The specific gap is stated plainly: there is a scarcity of NAMs designed to mimic precursor conditions and the dynamic process of disease progression in humans. Development, validation, and integrated use of such NAMs is described as a high-priority unmet need across cancer and other chronic diseases, which NIH notes are frequently interconnected.
Read strategically, that sentence contains three requirements most applications will only partially satisfy. The model must represent a precursor state rather than established disease. It must capture progression as a process rather than a static endpoint. And NIH wants development, validation, and integrated use, which means a proposal that builds a model without a qualification and application strategy is answering one third of the question.
What counts as a NAM here
The topic states that NAMs within its scope may include, but are not limited to, microphysiological systems such as organ-on-a-chip, 2D and 3D tissue systems, bioengineered human tissue models, in silico NAMs, and combinatorial NAMs. The named precursor examples are precancerous conditions, prediabetes, and preclinical Alzheimer's disease.
The inclusion of in silico and combinatorial NAMs matters commercially. A company with no wet lab can be responsive here through computational modeling and data integration, and a company that pairs a physical model with a computational layer is directly addressing the combinatorial category NIH names in every one of the four Institute sections.
NCI areas of interest
NCI seeks NAMs that accelerate research on precancer biology, cancer prevention, and the discovery of prevention and interception interventions. Its listed interests, which it states are not exhaustive, are human-derived precancerous organoids or other NAMs that help identify molecular mechanisms of precancer growth and exploitable targets for high-risk precancer interception; iPSC-derived or other bioengineered human tissue and immune system models mimicking aspects of human tumorigenesis; advanced biomaterials enabling innovative human-derived NAMs for precancer research; NAMs for discovery of cancer preventive, interceptive, or reversive agents; NAMs for biomarker discovery supporting early detection, efficacy evaluation, and risk stratification; and microphysiological and other combinatorial NAMs to predict human safety and toxicity of candidate agents for cancer prevention and interception.
What this tells you: NCI has decomposed the space into discovery tools, agent screening, biomarker discovery, and safety prediction, and named a separate scientific contact for nearly each one, plus contacts for pharmaceutical agent development, cancer dormancy and recurrence, and small business product development. The presence of the word "reversive" alongside preventive and interceptive is notable. NCI is signaling interest in agents that reverse precursor lesions, not only ones that halt them, and very few applications will propose a reversion endpoint.
NCATS areas of interest
NCATS is advancing disease-agnostic research using NAMs to understand and ultimately prevent drug-induced organ injury. It encourages human-based in vitro and in silico NAMs that illuminate the factors contributing to drug-induced organ injury so those reactions can be avoided or prevented, revealing actionable prevention mechanisms before clinical symptoms emerge. Its scientific interests center on innovative, scalable, and reproducible NAMs platforms that enable earlier interventions, reduce reliance on traditional animal models, and generate broadly applicable knowledge that helps treat and prevent disease onset and promotes long-term health across different populations.
What this tells you: NCATS is the only one of the four framed around a safety and toxicity problem rather than a disease. If your platform predicts organ injury, hepatotoxicity, nephrotoxicity, cardiotoxicity, or neurotoxicity, this is your door, and the disease-agnostic framing means you do not need a disease indication to be responsive. NCATS is also the Institute here that stated it may dedicate available funds to the topic area. The words scalable and reproducible should appear in your aims with data behind them.
NIA areas of interest
NIA seeks NAMs that identify biomarkers, protective pathways, and preventive therapeutics for age-related conditions and diseases including Alzheimer's disease and related dementias, through studies of aging biology and the intrinsic and extrinsic factors underlying resilience. Its listed interests are person-specific, cross-species, and combinatorial NAMs for biomarker discovery, identification of preventive therapeutics and interventions for age-related conditions and AD or ADRD, and prediction of safety and toxicity; neuronal and peripheral tissue NAMs derived from individuals with exceptional longevity, cognitive superagers, or individuals with resistance or resilience to AD and ADRD, used to identify protective pathways and test their ability to reduce or reverse disease phenotypes in iPSCs from patients with AD or ADRD; and in silico NAMs modeling behavioral, cognitive, and functional phenotypes along with extrinsic factors influencing disease risk and resilience.
What this tells you: NIA has described a specific experimental architecture, not just a technology category. Take tissue from people who resisted the disease, find the protective pathway, then test that pathway in patient-derived cells. A proposal that runs that full arc is unusually well matched. The phrase person-specific also signals interest in individualized rather than pooled models. And NIA is one of the components listed with Phase I headroom as high as $700,000 in the parent announcement table.
NIDA areas of interest
NIDA seeks human-relevant NAMs that accelerate research on addiction biology, substance use prevention, and intervention discovery. Its listed interests are human-derived iPSCs, organoids, bioengineered tissues, or other NAMs to identify molecular changes induced by addictive drugs and mechanisms contributing to addiction vulnerability; development and application of tools and methods, including in silico models, to integrate and analyze data from sources including epidemiological data and electronic health records in order to identify mechanisms, biomarkers, and candidate drugs for prevention, early intervention, and treatment of substance use disorders; and application of NAMs to decipher interactions among biological factors such as age and sex, behavioral factors such as exercise, and environmental factors such as nutrition and exposure to drugs and other substances that influence the trajectory of addiction and its comorbidities.
What this tells you: NIDA is the most accommodating of the four for data and software companies, because it explicitly invites electronic health record and epidemiological data integration as a NAM activity. NIDA also stated it may give special consideration to meritorious applications in this topic area. The gene by environment by behavior interaction framing is a distinctive third bullet that most applicants will skip.
What the non-awarding offices add
ORWH, OADR-ORWH, and THRO participate but do not award grants. Your application must be relevant to the objectives of at least one participating Institute or Center, which here means NCI, NCATS, NIA, or NIDA. Their stated interests function as scoring advantages layered on top of your primary Institute fit.
ORWH seeks NAMs relevant to women's health, specifically human-derived NAMs modeling hormone homeostasis across the life course and sex influences on precursor conditions and disease progression; biomarker identification in human-derived NAMs for early detection, prevention, translation, or risk stratification of conditions prevalent in females; evaluation of sex differences in human-derived organoids, microphysiological systems, iPSC-derived models, and other bioengineered tissues; and human microphysiological or combinatorial NAMs predicting safety and toxicity in female-relevant contexts.
OADR-ORWH is interested in projects using human-derived organoids, iPSCs, or other bioengineered human tissue and immune system models to investigate pre-clinical and established autoimmunity.
THRO supports NAMs development and use to prevent disease progression in American Indian and Alaska Native communities, encouraging models of diseases that disproportionately affect AI/AN populations such as diabetes and cancer. THRO adds a requirement that most applicants will not be able to satisfy retroactively: research should be culturally grounded and involve AI/AN communities and practices as much as possible. If you intend to claim THRO alignment, community partnership must be real and documented in the application, not asserted.
Practical read: sex differences are the cheapest and most defensible of these to build in, because evaluating sex differences in an existing model architecture is a design decision rather than a new capability. Doing it deliberately, with powered comparisons rather than a minimal sex-as-a-biological-variable statement, distinguishes an application at almost no cost.
MAHA and NAMs policy alignment
This topic is issued as part of the Make America Healthy Again initiative and aligns specifically with the New Approach Methodologies effort, under which expanded NAMs use is expected to enable earlier and more predictive insight into chronic disease mechanisms through human-relevant models such as organoids, computational simulations, and real-world data integration, improving prevention, diagnosis, and personalized treatment while reducing reliance on animal studies that often fail to replicate complex human conditions. EPA, FDA, and NIH have all committed to using NAMs going forward where appropriate.
The framing consequence is significant and specific to this topic. On most NIH applications, a preclinical package light on animal data is a weakness to be explained. Here, replacing animal work with a qualified human-relevant model is the point of the solicitation. Do not apologize for the absence of animal studies. Argue affirmatively that your model predicts human outcomes better, and cite the tri-agency commitment as the policy context that makes a qualified NAM a durable asset rather than a research curiosity.
Eligibility Requirements
To apply for an NIH SBIR or STTR award, your company must meet the core SBA criteria:
Organized for profit, with a place of business located in the United States, and the primary research performed in the United States
More than 50 percent directly owned and controlled by one or more individuals who are U.S. citizens or permanent resident aliens, by other for-profit small business concerns each majority owned by such individuals, or by a combination. Certain venture capital, hedge fund, and private equity ownership structures may qualify for SBIR under specific conditions, and Tribal, Alaska Native Corporation, Native Hawaiian Organization, and joint venture paths exist. Complex cap tables should be checked against 13 CFR Part 121 rather than assumed either way.
No more than 500 employees, including all affiliates. A subsidiary counts its parent's employees.
For SBIR, the Principal Investigator's primary employment must be with the small business at the time of award and for the duration of the project. For STTR, the PI may be primarily employed by the small business or by the partnering research institution.
For SBIR Phase I, the small business must perform at least two thirds of the research or analytical effort. For SBIR Phase II, at least half. For STTR, the small business performs at least 40 percent and a single partner nonprofit research institution performs at least 30 percent.
Companies with a substantial history of prior awards should confirm they meet the SBIR and STTR Phase I to Phase II Transition Rate and commercialization benchmarks, which can restrict new Phase I, Fast-Track, and Direct to Phase II eligibility for a period of one year. Applicants must also disclose overlapping federal work under the essentially equivalent work rule, which is a certification matter rather than a footnote. Heightened screening of foreign ownership and foreign influence applies under the 2026 reauthorization, and STTR applicants can face additional scrutiny because of the research institution partnership.
What a Competitive Application Looks Like
The trap on this topic is that NAMs are fashionable. NIH has funded organoids, microphysiological systems, and in silico models for years, and reviewers will have seen many applications proposing a model. The topic is not asking for a model. It is asking for a model of a precursor condition that captures progression, validated well enough to be used.
A precursor state, not a disease state. If your model represents established pathology, reframe it or propose the precursor version. Precancer, prediabetes, and preclinical Alzheimer's disease are the named examples, and the equivalent precursor in your indication is what NIH is asking for.
Progression as a measured process. NIH asks for the dynamic process of disease progression. That means longitudinal readouts and transition endpoints, not a single characterized timepoint. A model that shows a precursor becoming something else is answering the question a static model cannot.
A qualification and validation strategy, not just construction. The topic asks for development, validation, and integrated use. State what human outcome your model is claimed to predict, how you will demonstrate that predictivity, and against what reference data. This is also what makes the platform sellable, so it doubles as commercialization substance.
Scalability and reproducibility with data behind them. NCATS names both explicitly, and every buyer of a NAM platform, whether pharma or regulator, asks the same question. Batch-to-batch variability, operator independence, and throughput are legitimate Phase I aims.
A named customer and a regulatory posture. NIH small business awards are product development awards. For a NAMs platform the customer is usually a pharmaceutical developer, a CRO, or a regulator, and the value proposition is a decision they can make earlier or more confidently. Reference the FDA and EPA commitment to NAMs as the demand-side context.
Program officer contact before writing. With four Institutes, this is not optional here. The conversation determines your assignment request, tells you whether your topic is waiver-eligible for a larger budget, and surfaces overlap with existing awards. NCI has designated a small business product development contact for this topic specifically.
Common Reasons Applications Miss
Treating the Highlighted Topic as a NOFO and hunting Grants.gov for a topic-specific number that does not exist
Proposing a model of established disease when the topic asks for precursor conditions
Proposing a static model when the topic asks for the dynamic process of progression
Building the model and stopping there, with no validation, qualification, or use case, which answers one third of what the topic requests
Leaving the assignment request blank or picking the wrong Institute, so the application is read by a component with no stake in the science
Budgeting to the $700,000 component ceiling rather than the roughly $400,000 that Institutes actually award at Phase I
Omitting the fee from the budget, or requesting the wrong level, neither of which can be corrected after submission
Claiming THRO alignment without documented AI/AN community partnership
Treating the absence of animal data as a weakness to apologize for rather than the point of the solicitation
Starting federal registrations after drafting begins, then missing the receipt date on an eRA Commons validation error
Frequently Asked Questions
Is this a grant I can apply to directly?
No. This is an NIH Highlighted Topic, which is a statement of scientific priority rather than a Notice of Funding Opportunity. You apply through a broad NIH announcement, and for small businesses that means the NIH SBIR or STTR parent announcement, requesting assignment to one of the four participating Institutes.
Which funding opportunity number do I actually use?
For most small businesses it is PA-27-100, the NIH, CDC, and FDA Parent SBIR announcement covering R43 and R44 awards. If your project requires a formal university or nonprofit research partner, use PA-27-102, the Parent STTR announcement covering R41 and R42. Confirm the active number at the time you submit, since PA-27-100 closes in early April 2027 while this topic runs through September 2028.
Which of the four Institutes should I target?
NCI for precancer biology and cancer prevention or interception. NCATS for disease-agnostic platforms addressing drug-induced organ injury. NIA for aging, resilience, Alzheimer's disease and related dementias. NIDA for addiction biology, substance use, and data integration approaches. If your technology fits more than one, contact multiple program officers before choosing, because your assignment request shapes who reviews the application.
How much money can my company request?
The SBA statutory guidelines this cycle are $323,090 for Phase I and $2,153,927 for Phase II in total costs, including direct costs, indirect costs, and fee. Institute limits differ: the parent SBIR component table lists Phase I limits as high as $700,000 for NCI and NIA, while NCATS operates at the statutory guideline. In practice, NCI Phase I awards have clustered around $400,000 rather than at the ceiling. Contact your target Institute before budgeting above the guideline.
When is the deadline?
There is no deadline specific to this topic. You submit on the NIH standard small business receipt dates of January 5, April 5, and September 5 each year, with dates falling on weekends or federal holidays moving to the next business day. The topic expires on September 3, 2028, making January 5, 2027 through April 5, 2028 the realistic competing cycles.
How long until I receive funding?
Plan on approximately 9 months from submission to award start. An application submitted in the January 2027 cycle would typically have an earliest possible start date in the fall of 2027.
Do I have to give up equity or match the funds?
No. NIH SBIR and STTR Phase I and Phase II awards are non-dilutive and require no cost share. The exception is the Phase IIB Strategic Breakthrough Award, which requires not less than 100 percent matching funds from new private capital or from a government source other than a Phase I or Phase II SBIR or STTR award.
What counts as a New Approach Methodology under this topic?
The topic names microphysiological systems such as organ-on-a-chip, 2D and 3D tissue systems, bioengineered human tissue models, in silico NAMs, and combinatorial NAMs, and states the list is not exhaustive. The distinguishing requirement is not the technology type but the subject: the model should represent a precursor condition and the process of progression toward overt disease.
Does my model have to be human-derived?
Human relevance is the consistent thread across all four Institutes, and most listed interests specify human-derived material. NIA is the exception that explicitly includes cross-species NAMs among its interests. If your platform is not human-derived, the burden is to show why it predicts human outcomes better than the animal models NIH says are failing to translate.
Can I include a clinical trial?
The parent SBIR and STTR announcements are clinical trial optional, but acceptance varies by Institute and program, and several Institutes accept clinical trials through SBIR only. Given that this topic centers on preclinical model development, most responsive applications will not involve a clinical trial. If yours does, review the NIH Clinical Trial Definition and confirm with your target Institute, because the definition captures more study designs than founders expect.
Do I still need animal data?
Not necessarily, and on this topic the absence can be a strength. The topic is issued under the New Approach Methodologies effort, in which EPA, FDA, and NIH have committed to using human-relevant models to reduce reliance on animal studies that often fail to replicate complex human conditions. Argue that your model predicts human outcomes better rather than framing missing animal work as a limitation.
Does any Institute set aside dedicated funding for this topic?
Not guaranteed, but two made statements. NCATS states it may dedicate available funds to support applications in this topic area depending on the availability of funds, the number of meritorious applications, and competing priorities. NIDA states it may give special consideration to meritorious applications in the topic area. NCI and NIA made neither statement in this topic. Treat all of this as a favorable tilt rather than a reserved pool.
I already have feasibility data. Do I still need a Phase I?
Not necessarily. SBIR Direct to Phase II allows a company that has demonstrated the scientific and technical merit and feasibility normally expected from a Phase I, without having received a Phase I award for that project, to apply directly for Phase II. This authority is available for SBIR only and is not available under STTR. A validated platform plus new precursor-condition data is a common qualifying profile.
Do ORWH, OADR, and THRO award grants under this topic?
No. All three participate and publish areas of interest, but none awards grants. Your application must be relevant to the objectives of at least one of the awarding Institutes, meaning NCI, NCATS, NIA, or NIDA. Their interests are best used as additional strength within an application already aimed at one of the four.
What registrations do I need, and how long do they take?
SAM.gov with a Unique Entity ID, the SBA Company Registry, eRA Commons, and Grants.gov. eRA Commons access depends on completing the SBA Company Registry first, so the sequence matters. Allow at least six weeks, and start before you begin writing.
How BW&CO Helps
BW&CO is a non-dilutive federal funding advisory firm. We help deep-tech, biotech, medtech, and health technology founders convert agency priority signals like this one into funded awards.
On a topic with four awarding Institutes and four different budget ceilings, the highest-leverage work happens before a word of the application is written. That includes Institute selection and assignment strategy, program officer engagement, waiver eligibility assessment, Specific Aims development, full proposal build, budget and fee construction, commercialization and qualification planning, and Phase IIB matching capital positioning. Our team has helped clients secure more than $350 million in funding. Innovation Funding Simplified.
If you are building a New Approach Methodology and want an honest read on which Institute to target and whether you are competitive for the January 5, 2027 cycle, contact us for a fit assessment.
